News

Topline clinical data from ALS Phase 2b PARADIGM trial of PrimeC combination therapy is expected Q4 2023; Company is fully funded into Q2 2024 CAMBRIDGE, Mass., Oct. 2, 2023 /PRNewswire/ --...

SME status offers regulatory guidance and engagement in dialogue with EMA NeuroSense to open an EU office in Ulm, Germany Company plans to enroll patients at multiple sites across Europe in its...

Patents valid through 2038 Clinical topline results from Phase 2b ALS trial expected in H2 2023 CAMBRIDGE, Mass., Sept. 19, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN)...

Company to deliver poster presentation regarding its PARADIGM Phase 2b ALS study at NEALS CAMBRIDGE, Mass., Sept. 14, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN)...

Investors interested in meeting the executive team and hearing NeuroSense's strategy, updates, and upcoming catalysts are invited to register for the webinar event. CAMBRIDGE, Mass., Sept. 6, 2023...

ALS Phase 2b PARADIGM Trial Completed Patient Enrollment Topline results expected in Q-4 2023 Cash runway beyond topline clinical study readouts, into Q-2 2024 CAMBRIDGE, Mass., Aug. 16, 2023...

Investors interested in meeting the executive team and hearing NeuroSense's strategy, updates, and upcoming catalysts may register for the invitation-only event. CAMBRIDGE, Mass., July 17, 2023...

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it will participate in two upcoming conferences...

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today provided an update from its CEO, Alon Ben-Noon, on the...

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it has entered into a securities purchase...